A balloon tube that could spare patients a stoma after bowel surgery
NCT ID NCT05826743
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial is testing a device called COLO-BT™, a temporary balloon tube placed inside the bowel after colorectal surgery. The goal is to see if it can safely divert stool away from the surgical connection, potentially avoiding the need for a temporary ileostomy (a stoma bag). The study includes adults aged 19-80 who are undergoing colorectal surgery and compares the outcomes of those using the device with those receiving a standard protective stoma. Success is measured by whether patients avoid a stoma and have no major complications over six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- COLO-BT™, a temporary intraluminal bypass device (a balloon tube placed inside the bowel to divert stool away from the surgical connection)
- What this could lead to
- If effective, this device could offer a stoma-free recovery for many colorectal surgery patients, avoiding the need for a temporary ileostomy and its associated burdens.
- What could go wrong
- The device is still being tested, and its safety and effectiveness are not yet established. There is a risk of complications such as device migration, blockage, or failure to prevent leakage, and not all patients may be suitable candidates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 256 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: The patient must meet all study Inclusion Criteria as outlined below: * Adult males or females, 19-80 years of age, with signed informed consent * Subject whose anastomosis is expected to be located above 4cm from the anus, and at or below 15cm from the anus. (4cm \< inclusion target ≤ 15cm from the anus). ③ Patient must meet all other inclusion criteria to be eligible. While not required, if one or more of the following six risk factors for postoperative anastomotic leakage\[6,7,8\] is true, the patient will be considered a high-risk subject: \- Male \- Those with a body mass index of 30 or higher \- Current smoker \- Those who are on medication for diabetes \- Those with clinical stage III or higher malignant tumors \- Those who received chemo/radiation therapy before surgery ④ Those who are willing and able to participate in this clinical study, provide Informed Consent, and are willing to comply with the study procedures and follow up evaluations ⑤ Those who have willingness to undertake blood transfusion if required. Exclusion Criteria: Patients meeting any of the following Exclusion Criteria will not be eligible to participate in the study: 1. Women who are pregnant or breastfeeding 2. Those who receive emergency surgery 3. A person who is expected to need intensive medical care after the surgery due to a serious medical condition, with one or more of the following seven factors being true: * Patients with abnormal bone marrow function (those with hemoglobin less than 7g/dl, leukocyte count less than 4000/mm3, or platelet count less than 100,000/mm3 even after preoperative corrections) * Patients with severe liver damage or cirrhosis (those whose AST/ALT levels are more than three times the normal range or those diagnosed with cirrhosis) * Those with abnormal renal function (those who are on hemodialysis or who have a blood creatinine level of 2.0mg/dl or more before the surgery) * Those who have undergone cardiac or cerebrovascular stent procedure within the last 6 months * Those who have been diagnosed with pulmonary tuberculosis within the last 6 months or are undergoing drug treatment for pulmonary tuberculosis * Those who continuously administer steroids of 20mg/day or more within 30 days before the surgery * Patients with ASA (American Society of Anesthesiologists) score of 3 are evaluated by the investigator who determines whether or not patients with ASA score of 3 should be enrolled from the patient safety standpoint. Patients with ASA score higher than 3 are excluded from this study. * Patients who are required to undergo re-intervention to treat the anastomosis following intraoperative positive air leak test (However, patients who underwent complete reconstruction of the anastomosis in the presence of a positive air test, which therefore has made their risk of leak similar to those patients with a negative air leak test.) * Patients who are immune suppressed * Patients with severe diverticulosis * Patients with other colonic wall abnormalities in the likely area of the Outer Balloon and BT BAND application who may be at increased risk for device perforation or migration. 4. A person who has difficulty in mobility or is unable to communicate in general due to a psychiatric/neurologic disorder falling under one or more of the following: * Those diagnosed with dementia or Alzheimer's disease. * Those who have been diagnosed with schizophrenia or depression or are taking drugs due to this. * A person who has been diagnosed with disability due to intellectual disability. 5. Patients with intestinal perforation, abscess in the pelvis, or severe inflammation in the pelvis. 6. Those who have a history of undergoing major surgeries (major bowel resection/major gastrectomy, major hepatectomy) through laparotomy and are likely to have serious adhesions that may affect this surgery. 7. A patient who underwent a preoperative chemotherapy, but the anastomosis is expected to be located very close to the anus or in the anal canal, thus with a very high risk for complications of the anastomosis, or a patient whom the bowel function is expected to decrease significantly in the future. 8. Patients who had pre-operative radiotherapy should be excluded. 9. Patients with inflammatory bowel diseases such as ulcerative colitis, Crohn's disease, intestinal tuberculosis, or autoimmune diseases such as Bechet's disease. 10. Those who do not consent in writing to the study. 11. Experienced blood loss (\>750 cc) within 6 weeks before randomization. 12. Transfusion during surgery. 13. Any new sign of ischemia within 6 weeks before randomization. 14. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel all due to carcinomatosis within 6 weeks before randomization. 15. Known hypersensitivity or allergy to any of the components required for the procedure. 16. Exclusion criteria not specified above, but the patient is determined to be unsuitable for participation in this clinical study at the judgment of the researcher.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anastomotic leakage are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
-
Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo
RECRUITINGBuffalo, New York, 14203, United States
-
PennState Health - Milton S. Hershey Medical Center
RECRUITINGHershey, Pennsylvania, 17033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers